Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

81. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut.

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. OBJECTIVE: To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut. DESIGN: Natural experiment comparing two fixed cohorts from 1987 to 1997. SETTING: Seattle-Puget Sound and Connecticut surveillance (...) , epidemiology, and end results areas. PARTICIPANTS: Population based cohorts of male Medicare beneficiaries aged 65-79 drawn from the Seattle (n=94 900) and Connecticut (n=120 621) areas. MAIN OUTCOME MEASURES: Rates of screening for prostate cancer, treatment with radical prostatectomy and external beam radiotherapy, and prostate cancer specific mortality. RESULTS: The prostate specific antigen testing rate in Seattle was 5.39 (95% confidence interval 4.76 to 6.11) times that of Connecticut

BMJ2002 Full Text: Link to full Text with Trip Pro

82. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Ellison L, Cheli C D, Bright S, Veltri R W, Partin A W Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prostate-specific antigen (PSA) for population-based prostate cancer screening. Five strategies were identified. These were total PSA (tPSA) 4.0 ng/mg, free PSA/tPSA (f/tPSA), and complexed PSA (cPSA) 3.8, 3.4, and 3.0 ng/mg. Type of intervention Screening. Economic study

NHS Economic Evaluation Database.2002

83. Screening for prostate cancer

Screening for prostate cancer Screening for prostate cancer Screening for prostate cancer Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J. Screening for prostate cancer. Rockville: Agency for Healthcare Research and Quality (...) (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 16. 2002 Authors' objectives To examine the evidence of the benefits and harms of screening and earlier treatment in reducing prostate cancer mortality and to assist the US Preventive Services Task Force in making recommendations on this topic. Authors' conclusions We are unable to determine the net benefit of screening because we cannot establish the presence and, if present, the magnitude of benefit from screening. We can

Health Technology Assessment (HTA) Database.2002

84. Prostate Cancer: Screening

Prostate Cancer: Screening Screening: Prostate Cancer U.S. Preventive Services Task Force Prostate Cancer for Screening Release Date: December 2002 / Summary of Recommendations The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routine screening for prostate cancer using prostate specific antigen (PSA) testing or digital rectal examination (DRE). Rating: . Rationale : The USPSTF found good evidence that PSA screening can (...) detect early-stage prostate cancer but mixed and inconclusive evidence that early detection improves health outcomes. Screening is associated with important harms, including frequent false-positive results and unnecessary anxiety, biopsies, and potential complications of treatment of some cancers that may never have affected a patient's health. The USPSTF concludes that evidence is insufficient to determine whether the benefits outweigh the harms for a screened population. Supporting Documents

Publication 3262002

85. A quantitative analysis of the costs and benefits of prostate cancer screening

A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening Benoit R M, Gronberg H, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of prostate specific antigen (PSA), either alone or in combination with digital rectal examination (DRE), in screening for prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The (model) study population comprised males aged between 50 and 70 years with at least a 10-year life expectancy, who had been screened using

NHS Economic Evaluation Database.2001

86. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis

The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis Hoogendam A, Buntinx F, de Vet H C Authors' objectives To systematically review the literature in order to examine the diagnostic value of digital rectal (...) the studies, a narrative synthesis may have been more appropriate than statistical pooling. Nevertheless, the results appear to have been well pooled and the conclusions appear to be appropriate given the evidence. Implications of the review for practice and research Practice: The authors state that the DRE may have a place as an initial test when screening for prostate cancer. A negative result of DRE has a high predictive value. However, the moderate sensitivity should prevent the general practitioner

DARE.1999

87. Screening for prostate cancer, Norwegian review of international studies

Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Norwegian Knowledge (...) Centre for the Health Services. Screening for prostate cancer, Norwegian review of international studies. Norwegian Knowledge Centre for the Health Services (NOKC). SMM-Report 3/1999. 1999 Authors' objectives To evaluate the available documentation on screening for prostate cancer, as summarised in the INAHTA report 'Prostate Cancer Screening. Evidence Synthesis and Update'. Authors' conclusions The group of experts agree with the main conclusion from the INAHTA report; routine screening

Health Technology Assessment (HTA) Database.1999

88. Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)

Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Schersten T, Baile M A, Asua J, Jonsson E Citation Schersten T, Baile M A, Asua J, Jonsson E. Deteccion precoz del cancer de prostata (projecto (...) INAHTA). Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Vitoria Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-99-03. 1999 Authors' objectives

To summarize scientific evidence regarding the effectiveness and cost-effectiveness of mass screening for prostate cancer.

Authors' conclusions Mass screening for prostate cancer is not recommended because of lack of evidence regarding the benefits and the considerable risks of adverse effects

Health Technology Assessment (HTA) Database.1999

89. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Holmberg H, Carlsson P, Lofman O, Varenhorst E Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three-yearly prostate cancer screening for men aged 50-69 years. The screening involved digital rectal examination (DRE) by specialists and general practitioners (GPs) in the first screening round, DRE by GPs in the second round

NHS Economic Evaluation Database.1998

90. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillat D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Selley S, Donovan J (...) , Faulkner A, Coast J, Gillat D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1(2): 1-96 Authors' objectives To summarise the available evidence on the diagnosis, management and screening of early localised prostate cancer. Authors' conclusions There is no justification for the introduction of population screening. PSA testing should be limited to men with clinical evidence of prostate cancer who have a life expectancy of more than 10 years

Health Technology Assessment (HTA) Database.1997

91. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillatt D Authors' objectives To assess the clinical and cost-effectiveness of methods for the diagnosis, treatment and screening of early localised prostate cancer. Searching EMBASE, Cancerlit, MEDLINE, the Social Sciences Citation Index (...) studies. The studies included in this section of the review appear to have used needle biopsy as the reference standard. Participants included in the review No inclusion criteria relating to the characteristics of the participants were specified. The participants in the included studies were as follows. Diagnosis: males who were either volunteers or were referrals for suspected prostate cancer. Treatment: males with diagnosed prostate cancer. Screening: volunteers, attendees at clinics, and responders

DARE.1997

92. Cost-effectiveness analysis of prostatic cancer screening

Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Nakagawa S, Ebisui K, Sugimoto K, Nakanishi H, Kanemitsu N, Watanabe H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Standard tests in the screening of prostatic cancer (PC). Type of intervention Screening. Economic study type Cost-effective analysis. Study population A hypothetical cohort of 10,000 asymptomatic males for which estimations for PC screening were conducted for three age groups: 55-59, 60-69 and 70-79 years old. Setting Hospitals and clinics in Japan. Dates to which data relate The detection rate of PC, sensitivity and specificity of PC

NHS Economic Evaluation Database.1997

93. Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests')

Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') York: Centre for Reviews and Dissemination (CRD) 1997: 4 Authors' objectives To summarise the research evidence on screening for prostate cancer. Authors' conclusions There is increasing pressure on doctors to test men for the early detection of prostate cancer

Health Technology Assessment (HTA) Database.1997

94. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer: a review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

NIHR HTA programme1997

95. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review

Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Hanley J A, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hanley J A, McGregor M. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To evaluate the benefits, adverse health effects and costs of screening asymptomatic men for cancer of the prostate. Authors' conclusions From

Health Technology Assessment (HTA) Database.1995

96. Costs and effectiveness of prostate cancer screening in elderly men

Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Office of Technology Assessment. Costs and effectiveness of prostate cancer screening in elderly men. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1995: 130 Authors' objectives To examine the effectiveness, safety, and costs of screening for prostate cancer among asymptomatic men over 65 years in order to analyze the implications of a potential screening benefit under the U. S. Medicare program. Authors' conclusions Given the state of current

Health Technology Assessment (HTA) Database.1995

97. Prostate cancer screening in a large corporation population

Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Kantrowitz W, Doyle J, Semeraro J, Krane R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Prostate cancer screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Male employees of the Polaroid Corporation aged between 50 and 65 years. Setting Occupational. A large public corporation medical department in the United States. Dates to which data relate The start date of the screening programme was unclear. Resources used and costs were presented for the actual programme. The price year

NHS Economic Evaluation Database.1995

98. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Gustafsson O, Carlsson P (...) , Norming U, Nyman C R, Svensson H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The early detection of prostate cancer: a cost-effectiveness analysis of six screening strategies using different combinations of digital rectal

NHS Economic Evaluation Database.1995

100. An economic rationale for prostate cancer screening

An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening Benoit R M, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health (...) technology (a) Screening for prostate cancer using prostate-specific antigen(PSA) testing with and without digital rectal examination(DRE) (b) Screening for breast cancer using mammography with and without clinical breast examination. Type of intervention Secondary prevention Economic study type Cost-effectiveness analysis. Study population Men aged 50 to 70 and women aged 50-69. Setting The practice setting for breast cancer screening was not specified (it might be primary care). Prostate cancer

NHS Economic Evaluation Database.1994